Physician profile
Kari Koster
NPI 1952693731
$6,518.71
in general payments reported to CMS, 2019-2025
26 companies · $2,334 in 2025
The $2,334 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,089 · 2022: $852 · 2023: $1,101 · 2024: $1,143 · 2025: $2,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,578.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,053.40 | 2021-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $973.77 | 2021-2025 | |
| Alkermes, INC. | $868.43 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $716.60 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $678.29 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $382.95 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $355.95 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $345.57 | 2021-2025 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $144.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $141.99 | 2025 | Cobenfy |
| Bayer Healthcare Pharmaceuticals INC. | $133.71 | 2023-2025 | |
| Novo Nordisk INC | $129.60 | 2022-2025 | Wegovy |
| Xeris Pharmaceuticals, INC. | $109.59 | 2023-2024 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $89.00 | 2021 | |
| Eisai INC. | $86.43 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $67.70 | 2025 | |
| Ironshore Pharmaceuticals INC. | $35.46 | 2022 | |
| Supernus Pharmaceuticals, INC. | $32.30 | 2021 | |
| Exact Sciences Corporation | $30.71 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $27.33 | 2023 | Farxiga |
| Hologic Sales and Service, LLC | $26.43 | 2024 | Aptima |
| Idorsia Pharmaceuticals US INC | $21.22 | 2025 | Quviviq |
| Indivior INC. | $21.06 | 2023 | Sublocade |
| Avanir Pharmaceuticals, INC. | $20.14 | 2021 | |
| Lundbeck LLC | $14.87 | 2021 | |
| Corcept Therapeutics | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Koster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.